What Sent ResMed Stock Lower?
ResMed (RMD) shares dropped 9.1% on October 30, 2026, following its fiscal Q1 2027 earnings release. The company beat earnings and revenue estimates, with EPS of $2.91 and revenue of $1.41B. Despite 14% higher EPS YoY, revenue growth slowed to 5.9%. Peers also fell, with Stryker (SYK) down 6.4% after missing estimates. The broader market declined due to AI sector selloff. ResMed's stock is down 8.4% over the past year.
How this was made
The 30-second read
Why it matters
The mixed results created a sell‑off despite the beat, highlighting investor focus on growth momentum over short‑term profitability.
Market read
ResMed's earnings release generated a notable single‑stock move, influencing health‑care equipment sentiment and contributing to broader market weakness.
What to watch
ResMed's residential care software segment showed strength; potential upside from upcoming Q2 guidance.
Background
ResMed's Q1 FY2027 results were released on Oct 29, showing an earnings beat but the slowest revenue growth in five quarters, triggering a 9.1% stock decline.
Ticker impact
ResMed reported Q1 FY2027 earnings with EPS $2.91 beating estimates, but revenue growth slowed to 5.9%, leading to a 9.1% share drop on Friday.
likely further downside as investors price in slowing top‑line growth
Earnings beat alone would be supportive, but the deceleration in revenue and the 9% intraday fall suggest market concern.
Market effects
Health‑care equipment sector may see modest pressure as peers also fell, though the sector ETF XLV rose modestly.
U.S. market weakness contributed to the S&P 500's 1.8% decline, reflecting broader risk aversion.
Limited to U.S. equities; no immediate global macro link.
Counterpoint
The earnings beat and strong cash flow could support a rebound if revenue growth re‑accelerates in Q2.
Key entities
- companyResMed
Medical device maker specializing in sleep and respiratory solutions.
